Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes
Guangzhou Doublle Bioproduct Co., Ltd. has announced receiving Investigational New Drug (IND) clearance from China’s...
Cell-therapy
Suzhou Xueji Biotech’s XJ-MK-002 Gets FDA Orphan Drug Designation for CAMT
China-based cell therapy developer Suzhou Xueji Biotechnology Co., Ltd’s (HemaCell) XJ-MK-002, described as the world’s...
BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma
US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...
Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial
China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...
Jiuzhitang’s Stem Cell Therapy for Autism Receives NMPA Clinical Trial Approval
China-based Jiuzhitang Co. Ltd (SHE: 000989) announced receiving clinical trial approval from the National Medical...
Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform
Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with...
Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy
German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...
CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...
Cell Store and Cygenta Forge Strategic Alliance in Cell and Gene Therapy Field
Beijing-based biotech firms Cell Store, a biological sample cryopreservation technology platform, and Cygenta, a Contract...
Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE
According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has...
IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma
China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...
VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally
China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen...
IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore
China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...
Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus
China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a...
Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies
Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its...
Haichang Bio’s siRNA Drug HC016 Cleared for US Clinical Trials
China-based Zhejiang Haichang Biotech Co., Ltd has announced that its siRNA drug, HC016 complex lipid,...
iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies
Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7...
Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series
US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY)...
Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19
Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series...